title: Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.
authors.forename: Alain
authors.initials: A
authors.lastname: Ravaud
authors.forename: Christelle
authors.initials: C
authors.lastname: de la Fouchardière
authors.forename: Julien
authors.initials: J
authors.lastname: Asselineau
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Delord
authors.forename: Christine
authors.initials: C
authors.lastname: Do Cao
authors.forename: Patricia
authors.initials: P
authors.lastname: Niccoli
authors.forename: Patrice
authors.initials: P
authors.lastname: Rodien
authors.forename: Marc
authors.initials: M
authors.lastname: Klein
authors.forename: Bogdan
authors.initials: B
authors.lastname: Catargi
mesh_terms: D006801:Humans; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018276:Carcinoma, Medullary / Q000188:drug therapy; D007211:Indoles / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D000077210:Sunitinib; D013964:Thyroid Neoplasms / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib